UNSPSC 51313513: Dorastine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H22CLN3.2CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M52541M8X. The term dorastine hydrochloride is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule dorastine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, DORASTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dorastine hydrochloride bears US NLM identifiers UMLS ID C2699802 and NCI Concept Code C76062.

SMILES: CC1CCC(CN1)CCN2C3CCC(CC3C4C2CCN(C4)C)CL.CL.CL.

UNSPSC 51313513 Dorastine hydrochloride is a Commodity code that covers the procurement of specific pharmaceutical products by state and local health agencies, though recent solicitations under this code span a broader pharmaceutical supply ecosystem. State and local governments buying under this code are acquiring naloxone, generic multi-source pharmaceuticals, OTC products, and direct-to-manufacturer prescription fulfillment capabilities to support community health initiatives, employee health plans, and state pharmacy benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work ranges from direct procurement of discrete pharmaceutical units through competitive sealed bidding to strategic market research on direct-to-manufacturer distribution models and multi-state cooperative vendor panels for generic pharmaceuticals and OTC products.

Recent activity spans Florida, Texas, and Minnesota with broader geographic reach through MMCAP's multistate participation. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with bids due July 26, 2023. Minnesota's MMCAP, administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, seeking generic multi-source pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) for state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awards effective July 1, 2026. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs without a formal competitive timeline, signaling exploratory procurement strategy development ahead of formal solicitation.